Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 03, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Alcaftadine Ophthalmic Solution, 0.25% (OTC)".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 03, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Alcaftadine Ophthalmic Solution, 0.25% (OTC)".